394 related articles for article (PubMed ID: 11507217)
21. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo.
Buffa V; Negri DR; Leone P; Borghi M; Bona R; Michelini Z; Compagnoni D; Sgadari C; Ensoli B; Cara A
Viral Immunol; 2006; 19(4):690-701. PubMed ID: 17201664
[TBL] [Abstract][Full Text] [Related]
22. Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys.
Prevec L; Christie BS; Laurie KE; Bailey MM; Graham FL; Rosenthal KL
J Acquir Immune Defic Syndr (1988); 1991; 4(6):568-76. PubMed ID: 1902514
[TBL] [Abstract][Full Text] [Related]
23. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.
Caley IJ; Betts MR; Irlbeck DM; Davis NL; Swanstrom R; Frelinger JA; Johnston RE
J Virol; 1997 Apr; 71(4):3031-8. PubMed ID: 9060663
[TBL] [Abstract][Full Text] [Related]
24. Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice.
Jaffray A; Shephard E; van Harmelen J; Williamson C; Williamson AL; Rybicki EP
J Gen Virol; 2004 Feb; 85(Pt 2):409-413. PubMed ID: 14769898
[TBL] [Abstract][Full Text] [Related]
25. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity.
Faul EJ; Wanjalla CN; McGettigan JP; Schnell MJ
Virology; 2008 Dec; 382(2):226-38. PubMed ID: 18945463
[TBL] [Abstract][Full Text] [Related]
26. Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines.
zur Megede J; Otten GR; Doe B; Liu H; Leung L; Ulmer JB; Donnelly JJ; Barnett SW
J Virol; 2003 Jun; 77(11):6197-207. PubMed ID: 12743276
[TBL] [Abstract][Full Text] [Related]
27. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.
Haglund K; Forman J; Kräusslich HG; Rose JK
Virology; 2000 Mar; 268(1):112-21. PubMed ID: 10683333
[TBL] [Abstract][Full Text] [Related]
28. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.
Chen X; Rock MT; Hammonds J; Tartaglia J; Shintani A; Currier J; Slike B; Crowe JE; Marovich M; Spearman P
J Virol; 2005 May; 79(9):5537-47. PubMed ID: 15827168
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
[TBL] [Abstract][Full Text] [Related]
30. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
31. Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles.
Vajdy M; Gardner J; Neidleman J; Cuadra L; Greer C; Perri S; O'Hagan D; Polo JM
J Infect Dis; 2001 Dec; 184(12):1613-6. PubMed ID: 11740739
[TBL] [Abstract][Full Text] [Related]
32. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles.
Marsac D; Loirat D; Petit C; Schwartz O; Michel ML
J Virol; 2002 Aug; 76(15):7544-53. PubMed ID: 12097567
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.
Wanjalla CN; Faul EJ; Gomme EA; Schnell MJ
Vaccine; 2010 Dec; 29(1):130-40. PubMed ID: 20728525
[TBL] [Abstract][Full Text] [Related]
34. Kunjin virus replicon vectors for human immunodeficiency virus vaccine development.
Harvey TJ; Anraku I; Linedale R; Harrich D; Mackenzie J; Suhrbier A; Khromykh AA
J Virol; 2003 Jul; 77(14):7796-803. PubMed ID: 12829819
[TBL] [Abstract][Full Text] [Related]
35. Recombinant Mycobacterium smegmatis with a pMyong2 vector expressing Human Immunodeficiency Virus Type I Gag can induce enhanced virus-specific immune responses.
Kim BJ; Gong JR; Kim GN; Kim BR; Lee SY; Kook YH; Kim BJ
Sci Rep; 2017 Mar; 7():44776. PubMed ID: 28300196
[TBL] [Abstract][Full Text] [Related]
36. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.
Tan GS; McKenna PM; Koser ML; McLinden R; Kim JH; McGettigan JP; Schnell MJ
Virology; 2005 Jan; 331(1):82-93. PubMed ID: 15582655
[TBL] [Abstract][Full Text] [Related]
37. Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag.
Zhang H; Fayad R; Wang X; Quinn D; Qiao L
J Virol; 2004 Oct; 78(19):10249-57. PubMed ID: 15367590
[TBL] [Abstract][Full Text] [Related]
38. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.
Deml L; Bojak A; Steck S; Graf M; Wild J; Schirmbeck R; Wolf H; Wagner R
J Virol; 2001 Nov; 75(22):10991-1001. PubMed ID: 11602739
[TBL] [Abstract][Full Text] [Related]
39. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques.
Wagner R; Deml L; Notka F; Wolf H; Schirmbeck R; Reimann J; Teeuwsen V; Heeney J
Intervirology; 1996; 39(1-2):93-103. PubMed ID: 8957675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
